Esophageal cancer medical therapy: Difference between revisions
No edit summary |
|||
| Line 13: | Line 13: | ||
*[[Trastuzumab]] | *[[Trastuzumab]] | ||
[[Chemotherapy]] depends on the tumor type, but tends to be [[cisplatin]]-based (or [[carboplatin]] or [[oxaliplatin]]) every three weeks with [[fluorouracil]] (5-FU) either continuously or every three weeks. In more recent studies, addition of [[epirubicin]] (ECF) was better than other comparable regimens in advanced nonresectable cancer. | [[Chemotherapy]] depends on the tumor type, but tends to be [[cisplatin]]-based (or [[carboplatin]] or [[oxaliplatin]]) every three weeks with [[fluorouracil]] (5-FU) either continuously or every three weeks. In more recent studies, addition of [[epirubicin]] (ECF) was better than other comparable regimens in advanced nonresectable cancer. Chemotherapy may be given after surgery (adjuvant, i.e. to reduce risk of recurrence), before surgery (neoadjuvant) or if surgery is not possible; in this case, cisplatin and 5-FU are used. Ongoing trials compare various combinations of chemotherapy; the phase II/III REAL-2 trial - for example - compares four regimens containing [[epirubicin]] and either [[cisplatin]] or [[oxaliplatin]] and either continuously infused fluorouracil or [[capecitabine]].<ref name="pmid27576566">{{cite journal |vauthors=Ter Veer E, Haj Mohammad N, van Valkenhoef G, Ngai LL, Mali RMA, Anderegg MC, van Oijen MGH, van Laarhoven HWM |title=The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis |journal=J. Natl. Cancer Inst. |volume=108 |issue=10 |pages= |year=2016 |pmid=27576566 |doi=10.1093/jnci/djw166 |url=}}</ref><ref name="pmid28850174">{{cite journal |vauthors=Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S |title=Chemotherapy for advanced gastric cancer |journal=Cochrane Database Syst Rev |volume=8 |issue= |pages=CD004064 |year=2017 |pmid=28850174 |doi=10.1002/14651858.CD004064.pub4 |url=}}</ref><ref name="pmid9301445">{{cite journal |vauthors=Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L, Sahmoud T |title=Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer |journal=Eur. J. Cancer |volume=33 |issue=8 |pages=1216–20 |year=1997 |pmid=9301445 |doi= |url=}}</ref> | ||
==References== | ==References== | ||
Revision as of 14:30, 7 December 2017
|
Esophageal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Esophageal cancer medical therapy On the Web |
|
American Roentgen Ray Society Images of Esophageal cancer medical therapy |
|
Risk calculators and risk factors for Esophageal cancer medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Overview
The predominant therapy for esophageal cancer is surgical resection. Adjunctive chemotherapy and radiation may be required. Drugs approved for the treatment of esophageal cancer include ramucirumab, docetaxel, trastuzumab, ramucirumab.
Medical Therapy
Chemotherapy
Drugs approved by the Food and Drug Administration (FDA) for esophageal cancer are:
Chemotherapy depends on the tumor type, but tends to be cisplatin-based (or carboplatin or oxaliplatin) every three weeks with fluorouracil (5-FU) either continuously or every three weeks. In more recent studies, addition of epirubicin (ECF) was better than other comparable regimens in advanced nonresectable cancer. Chemotherapy may be given after surgery (adjuvant, i.e. to reduce risk of recurrence), before surgery (neoadjuvant) or if surgery is not possible; in this case, cisplatin and 5-FU are used. Ongoing trials compare various combinations of chemotherapy; the phase II/III REAL-2 trial - for example - compares four regimens containing epirubicin and either cisplatin or oxaliplatin and either continuously infused fluorouracil or capecitabine.[1][2][3]
References
- ↑ Ter Veer E, Haj Mohammad N, van Valkenhoef G, Ngai LL, Mali R, Anderegg MC, van Oijen M, van Laarhoven H (2016). "The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis". J. Natl. Cancer Inst. 108 (10). doi:10.1093/jnci/djw166. PMID 27576566. Vancouver style error: initials (help)
- ↑ Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S (2017). "Chemotherapy for advanced gastric cancer". Cochrane Database Syst Rev. 8: CD004064. doi:10.1002/14651858.CD004064.pub4. PMID 28850174.
- ↑ Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L, Sahmoud T (1997). "Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer". Eur. J. Cancer. 33 (8): 1216–20. PMID 9301445.